奥精医疗科技股份有限公司 关于2024年年度报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于 2025 年4月26日在上海证券交易所网站 （www.sse.com.cn）上披露了《2024年年度报告》。经事后核查发现，因部分信息有误，现对相关内容 予以更正，具体更正如下： 更正前： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销售客户及主要供应商 情况之A.公司主要销售客户情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688613 证券简称：奥精医疗 公告编号：2025-027 公司前五名客户 √适用 □不适用 单位：万元 币种：人民币 ■ 报告期内向单个客户的销售比例超过总额的50%、前5名客户中存在新增客户的或严重依赖于少数客户 的情形 □适用 √不适用 更正后： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销售客户及主要供应商 情况之A.公司主要销售客户情况 公司前五名 ...

5月30日，奥精医疗的资金流向如下：- 主力资金净流入877.0万元；- 游资资金净流入479.45万元；- 散 户资金净流出1356.45万元。 截至2025年5月30日收盘，奥精医疗(688613)报收于18.93元，上涨0.48%，换手率6.4%，成交量8.77万 手，成交额1.68亿元。 当日关注点 交易信息汇总 公司公告汇总奥精医疗：关于2024年年度报告的更正公告 奥精医疗科技股份有限公司于2025年4月26日在上海证券交易所网站上披露了《2024年年度报告》。经 核查发现部分内容有误，现对相关情况进行更正。更正涉及第五部分报告期内主要经营情况中关于主营 业务分析的收入和成本分析中主要销售客户及主要供应商情况。更正前，公司表示报告期内向单个客户 的销售比例未超过总额的50%，前5名客户中不存在新增客户或严重依赖少数客户的情形。更正后，公 司确认报告期内向单个客户的销售比例超过总额的50%，前5名客户中存在新增客户且严重依赖少数客 户，其中客户一和客户四是2024年新增客户。公司对由此给投资者带来的不便深表歉意，并承诺将加强 定期报告编制过程中的校对工作，提高信息披露质量。除上述更正外，《2024年 ...

2024年，奥精医疗实现营业总收入2.06亿元，同比下降9.03%；归属于上市公司股东的净利润 为-1266.22万元，上年同期为5423.18万元；归属于上市公司股东的扣非净利润为-2837.11万元，上年同 期为2576.62万元；经营活动产生的现金流量净额为-1960.33万元，上年同期为5167.85万元 | | | | | 单位:元 币种:人民币 | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 本期比上 年同期增 | 2022年 | | | | | 減(%) | | | 营业收入 扣除与主营业务无关 | 206.033.014.77 | 226. 475. 894. 98 | -9. 03 | 245. 305. 139. 72 | | 的业务收入和不具备 商业实质的收入后的 | 200. 430. 853. 46 | 218. 427. 930. 77 | -8.24 | 240. 282. 309. 74 | | 营业收入 | | | | | | 归属于上市公司股东 | -12.662.162.69 | 54.231.84 ...

股本股东变化 股东BioVeda China RMB Investment Limited于2025年2月25日至2025年5月25日间合计减持34.51万股，占 公司目前总股本的0.2519%，变动期间该股股价上涨0.76%，截止5月23日收盘报17.28元。本次减持计划 实施前，BioVeda持有奥精医疗7,584,445股股份，占奥精医疗总股份的5.6%。截至2025年5月25日， BioVeda累计已减持公司股份345,087股，占公司总股本比例为0.25%，减持总金额为5,913,162.50元，减 持价格区间为17.00～17.19元/股。当前持股数量为7,239,358股，持股比例为5.28%。 截至2025年5月30日收盘，奥精医疗（688613）报收于18.93元，较上周的17.28元上涨9.55%。本周，奥 精医疗5月30日盘中最高价报19.68元。5月29日盘中最低价报17.16元。奥精医疗当前最新总市值25.94亿 元，在医疗器械板块市值排名108/126，在两市A股市值排名4464/5146。 本周关注点 公司公告汇总 奥精医疗科技股份有限公司2024年年度报告显示，报告期内公司实现 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 500 million, representing a growth of 25% year-over-year[13]. - In 2024, the company's operating revenue decreased by 9.03% year-on-year to CNY 206,033,014.77, primarily due to the implementation of centralized procurement for orthopedic artificial bone repair materials, which led to a decline in unit ex-factory prices despite increased sales volume[19]. - The net profit attributable to shareholders was -CNY 12,662,162.69 in 2024, a decrease of 123.35% compared to the previous year, driven by increased costs and market activity expenses following the centralized procurement[21]. - The cash flow from operating activities showed a significant decline of 137.93%, resulting in a net outflow of -CNY 19,603,287.90, attributed to reduced receivables and increased operational costs[21]. - The company's total assets increased by 0.85% year-on-year, reaching CNY 1,539,163,337.61, indicating stability in asset management[20]. - The basic earnings per share for 2024 was -CNY 0.09, a decline of 121.95% from the previous year, indicating significant financial challenges[20]. - The weighted average return on equity decreased to -0.91%, down 4.99 percentage points from the previous year, highlighting reduced profitability[20]. - The company's revenue for the reporting period was approximately ¥206 million, a decrease of 9.03% compared to the previous year due to the implementation of centralized procurement, which lowered unit prices despite increased sales volume[88]. - Operating costs increased by 51.90% year-on-year, primarily due to the high costs associated with the new dental implant product line and increased sales volume of artificial bone repair materials[89]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[13]. - The company completed the acquisition of HumanTech Dental in 2024, expanding into the dental implant business and increasing sales personnel and marketing activities[21]. - The company is actively pursuing international market expansion, having obtained medical device registration for its artificial bone repair product "BonGold" in Malaysia and is in the registration process in Vietnam and Indonesia[56]. - The company aims to address the challenges of bone defect repair by developing ideal artificial bone repair materials with favorable physicochemical and biological properties[43]. - The company is currently involved in key national R&D projects, including the "14th Five-Year Plan" project for personalized bone regeneration materials[72]. - The company plans to accelerate overseas business development, focusing on international markets for dental implants and artificial bones, aiming for significant growth by 2025[135]. - The company will enhance domestic market marketing efforts, leveraging existing customer resources and marketing networks to increase market share and product penetration[135]. Research and Development - The company has invested RMB 50 million in R&D for innovative medical technologies, aiming to improve operational efficiency by 10%[13]. - Research and development expenses accounted for 18.82% of operating revenue, down from 20.09% in the previous year, reflecting a strategic shift in resource allocation[20]. - R&D investment intensity is among the highest in the industry, with breakthroughs including the registration of mineralized collagen/polyester artificial bone repair materials and absorbable collagen hemostatic sponges[30]. - The company has developed a series of mineralized collagen artificial bone repair products, including "BonGold," which is the first domestic artificial bone repair product to obtain FDA 510(k) market access in the U.S.[34]. - The company has initiated a national key R&D project focused on the development of biomimetic collagen-based materials for cranial defect repair, which has entered the animal testing preparation stage[58]. - The company has made significant progress in its product pipeline, with successful registration applications for mineralized collagen/polyester artificial bone repair materials and absorbable collagen hemostatic sponges[82]. - The company has established a postdoctoral research workstation approved by the Beijing Human Resources and Social Security Bureau, enhancing its innovation capabilities and talent development in biomedical materials[83]. Product Development and Innovation - New product development includes the launch of a next-generation medical device, expected to contribute an additional RMB 100 million in revenue[13]. - The company’s production capacity for mineralized collagen artificial bone repair materials reached a standardized capacity of 2 million boxes per year, supporting clinical supply and market expansion[31]. - The company has developed a hemostatic collagen sponge that received Class III medical device registration in China, enhancing its product line in regenerative medicine[71]. - The company has completed the design planning for orthopedic and oral surgical instruments, with an expected completion of one instrument by the end of 2025[64]. - The company has achieved significant progress in the development of nerve conduit and artificial dura mater, with total investments of ¥5,000.00 million and ¥1,800.00 million respectively[64]. Risk Management - The company has no significant risks that could adversely affect its operations, ensuring a stable outlook for the upcoming year[4]. - The company faces risks related to the renewal of medical device product registration certificates, which are valid for five years, potentially impacting production and operations[75]. - The company is subject to strict regulatory oversight, and any failure to adapt to changes in healthcare policies could adversely affect its operations[80]. - The company is enhancing its production and operational management to mitigate risks associated with centralized procurement and potential price declines in the orthopedic market[80]. Corporate Governance and Management - The board of directors has approved a profit distribution plan, although no dividends will be issued this year due to reinvestment strategies[5]. - The company has implemented a new incentive plan for key personnel, with multiple first-time grants of restricted shares totaling 1,016,250 shares across various executives[144]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to RMB 12.51 million[151]. - The company has a cash dividend policy that prioritizes cash distributions, aiming for a minimum of 30% of the average distributable profit over the last three years to be distributed in cash[169]. - The company has established a comprehensive welfare system, including mandatory social insurance and supplementary medical funds for employees[165]. Environmental and Social Responsibility - The company invested 7.83 million yuan in environmental protection during the reporting period[190]. - The company has established a comprehensive environmental protection management system and conducts training on environmental protection[194]. - The company actively engages in social responsibility, focusing on the needs of stakeholders and promoting sustainable development[196].

证券代码：688613 证券简称：奥精医疗 公告编号：2025-027 奥精医疗科技股份有限公司 关于2024年年度报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于 2025 年4月26日在上海证 券交易所网站（www.sse.com.cn）上披露了《2024年年度报告》。经事后核查发现， 因部分信息有误，现对相关内容予以更正，具体更正如下： 更正前： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销 售客户及主要供应商情况之A.公司主要销售客户情况 公司前五名客户 √适用 □不适用 单位：万元 币种：人民币 占年度销售总额 是否与上市公司 序号 客户名称 销售额 比例（%） 存在关联关系 合计 / 6,796.84 33.91 / □适用 √不适用 更正后： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销 售客户及主要供应商情况之A.公司主要销售客户情况 公司前五名客户 √适用 □不适用 单位： ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-027 奥精医疗科技股份有限公司 关于2024年年度报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于 2025 年4月26日在上海证 券交易所网站（www.sse.com.cn）上披露了《2024年年度报告》。经事后核查发现， 因部分信息有误，现对相关内容予以更正，具体更正如下： 更正前： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销 售客户及主要供应商情况之A.公司主要销售客户情况 公司前五名客户 更正后： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销 售客户及主要供应商情况之A.公司主要销售客户情况 1 公司前五名客户 √适用 □不适用 √适用 □不适用 单位：万元 币种：人民币 | 序号 | 客户名称 | 销售额 | 占年度销售总额 比例（%） | 是否与上市公司 存在关联关系 | | --- | --- | --- | ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-026 奥精医疗科技股份有限公司 关于2025年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称："公司"）践行"以投资者为本" 的发展理念，为维护全体股东利益，基于对公司未来发展前景的信心、对公司价 值的认可和切实履行社会责任，公司于2024年7月17日发布了《2024年度"提质 增效重回报"行动方案》（以下简称"《行动方案》"）。2024年度，公司在聚 焦主营业务、提升创新能力、完善公司治理、保障投资者权益、树立良好的资 本市场形象等方面取得了一定成效。为能在2025年更好地延续上述方面取得的 良好成绩，公司制定了《2025年度"提质增效重回报"行动方案》，具体情况 如下： 2024年公司市场开拓步伐加快，共新开发医院900余家，其中由于骨科人工 骨全国集采落地实施新增的医院数量为800余家，终端医院数量与去年同期相比 增加90%。公司组织和参与的行业展会、学术沙龙会、招商会全年共近百场 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-025 重要内容提示： 奥精医疗科技股份有限公司 持股5%以上股东减持股份计划完成暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 ● 大股东持股的基本情况 本次减持计划实施前，奥精医疗科技股份有限公司（以下简称 "公司" 或"奥精医疗"）股东BioVeda China RMB Investment Limited China RMB Investment Limited（以下简称 "BioVeda"）持有奥精医疗 7,584,445股股份，占奥精医疗总股份的5.6%。 ● 减持计划的实施结果情况 2025年1月24日，公司披露了《奥精医疗科技股份有限公司股东集中竞价减持股份计划公告》（公告编 号：2025-003），BioVeda China RMB Investment Limited计划通过集中竞价、大宗交易方式减持奥精医 疗股份不超过1,355,515股，占奥精医疗总股份的1%。 公司于近日收到BioVeda China RMB ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-025 奥精医疗科技股份有限公司 持股 5%以上股东减持股份计划完成 暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，奥精医疗科技股份有限公司（以下简称 "公司" 或"奥精医疗"）股东 BioVeda China RMB Investment Limited China RMB Investment Limited（以下简称 "BioVeda"）持有奥精医疗 7,584,445 股股份，占奥精医疗总股份的 5.6%。 减持计划的实施结果情况 | 股东名称 | BioVeda | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：- | | | | 持股数量 | 7,58 ...